Voyager Therapeutics, Inc. (VYGR)

Market Cap	311.76M
Revenue (ttm)	163.78M
Net Income (ttm)	25.88M
Shares Out	54.63M
EPS (ttm)	0.47
PE Ratio	12.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	432,987
Open	6.11
Previous Close	6.22
Day's Range	5.67 - 6.15
52-Week Range	5.67 - 11.72
Beta	0.89
Analysts	Strong Buy
Price Target	17.00 (+197.87%)
Earnings Date	Nov 12, 2024

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Analyst Forecast

According to 8 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 197.87% from the latest price.

Price Target

$17.0

(197.87% upside)

Analyst Consensus: Strong Buy